Unknown

Dataset Information

0

Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension.


ABSTRACT: To evaluate the efficacy and safety of extended dosing with mipomersen in patients with familial hypercholesterolaemia (HC) taking maximally tolerated lipid-lowering therapy.A planned interim analysis of an ongoing, open-label extension trial in patients (n = 141) with familial HC receiving a subcutaneous injection of 200 mg mipomersen weekly plus maximally tolerated lipid-lowering therapy for up to 104 weeks. The mean changes in low-density lipoprotein cholesterol (LDL-C) from baseline to weeks 26 (n = 130), 52 (n = 111), 76 (n = 66), and 104 (n = 53) were -28, -27, -27, and -28%; and in apolipoprotein B -29, -28, -30, and -31%, respectively. Reductions in total cholesterol, non-high-density lipoprotein-cholesterol, and lipoprotein(a) were comparable with decreases in LDL-C and apolipoprotein B levels. Mean high-density lipoprotein cholesterol increased from baseline by 7 and 6% at weeks 26 and 52, respectively. The long-term safety profile of mipomersen was similar to that reported in the associated randomized placebo-controlled Phase 3 trials. Adverse events included injection site reactions and flu-like symptoms. There was an incremental increase in the median liver fat during the initial 6-12 months that appeared to diminish with continued mipomersen exposure beyond 1 year and returned towards baseline 24 weeks after last drug dose suggestive of adaptation. The median alanine aminotransferase level showed a similar trend over time.Long-term treatment with mipomersen for up to 104 weeks provided sustained reductions in all atherosclerotic lipoproteins measured and a safety profile consistent with prior controlled trials in these high-risk patient populations. CLINICALTRIALS.GOV: NCT00694109.

SUBMITTER: Santos RD 

PROVIDER: S-EPMC4344956 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension.

Santos Raul D RD   Duell P Barton PB   East Cara C   Guyton John R JR   Moriarty Patrick M PM   Chin Wai W   Mittleman Robert S RS  

European heart journal 20131223 9


<h4>Aims</h4>To evaluate the efficacy and safety of extended dosing with mipomersen in patients with familial hypercholesterolaemia (HC) taking maximally tolerated lipid-lowering therapy.<h4>Methods and results</h4>A planned interim analysis of an ongoing, open-label extension trial in patients (n = 141) with familial HC receiving a subcutaneous injection of 200 mg mipomersen weekly plus maximally tolerated lipid-lowering therapy for up to 104 weeks. The mean changes in low-density lipoprotein c  ...[more]

Similar Datasets

| S-EPMC8802375 | biostudies-literature
| S-EPMC6779015 | biostudies-literature
| S-EPMC4962457 | biostudies-literature
| S-EPMC10842202 | biostudies-literature
| S-EPMC10200237 | biostudies-literature
| S-EPMC7501126 | biostudies-literature
| S-EPMC10580679 | biostudies-literature
| S-EPMC5821682 | biostudies-literature
| S-EPMC5319045 | biostudies-literature
| S-EPMC6850399 | biostudies-literature